Guardian Connect

by Medtronic  · Based in Ireland → — A continuous glucose monitoring (CGM) system that provides real-time glucose level monitoring and alerts on mobile devices, with AI capabilities for predicting blood glucose changes.
Endocrinology Family Medicine Internal Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Subscription-based or outright purchase

Overview

The Medtronic Guardian Connect system is a continuous glucose monitoring (CGM) system designed to help individuals with diabetes, aged 14 to 75 years, proactively manage their glucose levels. It continuously measures glucose levels in the interstitial fluid under the skin every five minutes, transmitting this data via Bluetooth to a compatible smartphone app. The system is notable for its predictive algorithms and AI capabilities, which can alert users to potential high or low glucose events up to 60 minutes in advance. This allows individuals to take preventative action and can significantly improve time spent within the target glucose range. The Guardian Connect system also offers exclusive access to the Sugar.IQ™ smart diabetes assistant, an AI-powered app developed with IBM Watson Health, which analyzes how an individual’s glucose levels respond to various factors like food intake, insulin dosages, and daily routines, providing personalized insights.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Real-time glucose monitoring on smartphone
  • Predictive alerts for high and low glucose events (up to 60 minutes in advance)
  • Sugar.IQu2122 smart diabetes assistant (AI-powered insights)
  • Customizable alerts and volume adjustments
  • Data sharing with care partners and healthcare professionals via CareLinku2122 Connect
  • Tracks daily activities (exercise, insulin, meals) to understand glucose impact
  • 7-day sensor wear
  • Water-resistant sensor
  • High accuracy (9% MARD for arm, 10.5% MARD for abdomen)
  • Compatible with iOS and Android devices

Use Cases

  • Continuous glucose monitoring for individuals with Type 1 and Type 2 diabetes (ages 14-75)
  • Proactive management of blood glucose levels for people using multiple daily insulin injections (MDI)
  • Preventing hypoglycemic and hyperglycemic events through predictive alerts
  • Personalized diabetes management insights through AI analysis of glucose data
  • Remote monitoring by care partners and healthcare professionals
  • Understanding the impact of diet, exercise, and medication on glucose levels

What Physicians Need to Know

Key Capabilities
Real-time continuous glucose monitoring (CGM) with readings every five minutes. Customizable predictive alerts for high and low glucose events up to 60 minutes in advance. Displays glucose levels, trends, and rate of change on a smartphone app. Integrates with the Sugar.IQu2122 diabetes assistant app (iOS only) for personalized insights based on food, exercise, and insulin. Allows users to track daily activities like exercise, insulin, and meals. Enables sharing of glucose data with care partners and healthcare professionals via the CareLinku2122 system.
Clinical Utility
Aids in proactive diabetes management by providing predictive alerts to help avoid high and low glucose events. Helps patients using multiple daily injections (MDI) to manage their diabetes more effectively. Clinical studies have shown it accurately alerts patients of hypoglycemic events (98.5% detection rate). Real-world data indicates that using Guardian Connect with the Sugar.IQ app can increase Time in Range (TIR) by 4.1%, representing about one extra hour per day. Predictive alerts have been shown to reduce low sensor glucose excursions by almost twofold and high sensor glucose excursions by fourfold. The system is intended to complement, not replace, information from standard blood glucose monitoring devices.
Integration Options
Connects to the Guardian Connect app on compatible iOS and Android smartphones. Data automatically uploads to the CareLinku2122 Therapy Management System for healthcare providers. Care partners can receive real-time glucose data and text alerts through the CareLinku2122 Connect web app. Compatible with smartwatches for push notifications. The Sugar.IQu2122 diabetes assistant app (iOS only) integrates with Guardian Connect data.
Compliance Status
U.S. Food and Drug Administration (FDA) approved for people with diabetes aged 14 to 75 years. Health Canada approved. Requires a prescription.
Pricing Model
Available through subscription plans, which may include the transmitter kit and monthly sensor shipments. Initial setup cost for the CGM device can be higher, with ongoing costs for sensors. Pricing can vary, with options for discounts on annual plans. Special B2B pricing may be available for medical professionals.
User Experience
Displays glucose data on a smartphone, offering a discreet way to monitor levels. Customizable alerts with adjustable volume and mute options. Easy sensor application process. Requires calibration with a blood glucose meter at least every 12 hours (Guardian Sensor 3). The app provides a user-friendly interface for calibration, logging events (exercise, meals, insulin), and viewing reports. Water-resistant for everyday activities.
Support Quality
Offers 24-hour technical support. Provides personalized support and training, including an onboarding program. Includes a 1-year manufacturer warranty.
Implementation Complexity
Requires a compatible mobile device (iOS or Android). Initial setup involves pairing the transmitter with the app and an internet connection. Training is provided for users, covering CGM basics, sensor insertion and calibration, and app features. The sensor is designed for up to 7 days of continuous wear. Requires regular calibration with fingerstick blood glucose measurements.
Evidence Base
Clinical studies demonstrate accuracy in detecting hypoglycemic events. Real-world data shows improved Time in Range and reduced glucose excursions when used with the Sugar.IQ app. A clinical study comparing Guardian Connect to Freestyle Libre found Guardian Connect to be superior in accuracy (MARD of 9.7% vs. 17.5%). Machine learning models trained on Guardian Connect data achieved 90% accuracy in predicting hypoglycemic events within a two-hour window. The Guardian Sensor 3 has a Mean Absolute Relative Difference (MARD) of 8.7% for arm placement and 10.5% for abdomen placement.
Physician Tip

Emphasize to patients that Guardian Connect is an adjunctive tool and does not replace fingerstick blood glucose measurements for therapy adjustments. Leverage the CareLinku2122 system for seamless access to patient data, enabling more productive office visits and informed treatment decisions. Encourage patients to utilize the predictive alerts and the Sugar.IQu2122 app (if applicable) to proactively manage glucose levels and improve Time in Range. Advise patients on the importance of consistent calibration for optimal sensor accuracy. Discuss compatible devices and proper app settings to ensure patients receive all necessary alerts.

The Guardian Connect system integrates with the Medtronic CareLinku2122 Therapy Management System for healthcare professional access to patient data and the Sugar.IQu2122 diabetes assistant app (iOS only) for personalized insights. It is a standalone CGM system and does not directly integrate with insulin pumps, though it can be used by individuals on multiple daily injections or those using insulin pumps separately. Data can be viewed on compatible iOS and Android smartphones, and push notifications can be sent to smartwatches.

Details

Category Endocrinology & Metabolic AI, Wearables & Remote Monitoring (RPM)
Pricing Subscription-based or outright purchase
  • Annual cost without subscription: ~$4988.00 CAD (includes transmitter); Subscription service (Canada): ~$3950.10 - $3951.10 CAD annually (saves ~$1036.90 - $1037.90 annually, includes transmitter and discounted sensors); UK subscription: £199/month (annual plan, includes transmitter kit, 60 sensors/year, new transmitter every 12 months); Trial pack (UK): £50.00 (includes loan transmitter, 2 sensors, deposit required)
DeploymentCloud-based (CareLink™ Personal)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Unknown AI-estimated

The Guardian Connect system received U.S. FDA approval on March 12, 2018, for continuous or periodic monitoring of glucose levels in the interstitial fluid for patients aged 14 to 75 years with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices.
Integrations
EHR Not specified
Specialties Endocrinology, Family Medicine, Internal Medicine

What the Web Says

The Medtronic Guardian Connect is a continuous glucose monitoring (CGM) system designed for individuals with diabetes, particularly those on multiple daily injections (MDI). It provides real-time glucose readings every five minutes via a smartphone app (primarily iOS compatible) and offers predictive alerts for high and low blood sugar events. The system also includes the Sugar.IQ app, which uses AI to analyze glucose data and provide personalized insights to help users manage their diabetes more effectively.

Overall: Mixed

Strengths

  • Real-time glucose data and trends available on a smartphone app.
  • Ability to share live blood sugar data and alerts with up to five caregivers, including SMS alerts for highs and lows.
  • Predictive alerts for impending high and low glucose events, aiding in proactive diabetes management.
  • The Sugar.IQ companion app provides personalized insights and can improve Time in Range.
  • Painless and relatively simple sensor insertion.
  • Customizable alerts for different times and days.
  • Waterproof transmitter.

Limitations

  • Requires frequent calibration (at least twice daily), and data stops if calibration is missed.
  • Limited phone compatibility, primarily iOS devices.
  • Sensor life is typically 6-7 days, which is shorter than some competitors, and requires a 2-hour warm-up period.
  • Higher initial setup cost compared to some other CGM systems.
  • Can generate annoying false alarms.
  • Not approved by the FDA for making direct therapy adjustments without adjunct blood glucose meter readings.

Based on reviews from: Blue Circle Diabetes Foundation, Reddit, Every day ups and downs, a diabetes blog, Medium, U.S. Pharmacist, Integrated Diabetes Services, Medtronic, EndoText.org, Ovid, Frontiers, Washington State Health Care Authority, American Pharmacists Association, DocHub, DOKUMEN.PUB, Scribd

Last updated: 2026-08-05

Ratings & Reviews

Rate Guardian Connect

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Medtronic Newsroom
Medtronic Receives FDA Approval for Guardian Connect Continuous Glucose Monitoring (CGM) System for People Living with Diabetes
Medtronic announced FDA approval for its Guardian Connect continuous glucose monitoring (CGM) system for individuals aged 14-75, making it the first smart standalone CGM to offer predictive alerts for high and low glucose events up to 60 minutes in advance.
2018-03
The Medical Futurist
Medtronic's Smart Continuous Glucose Monitoring System Rolls Out This Summer
Following FDA approval, Medtronic's Guardian Connect system, an algorithm-based CGM with predictive alerts for people using multiple daily insulin injections, was set to roll out in the summer of 2018.
2018-03
diaTribe.org
Medtronic Announces FDA Approval of Guardian Connect Mobile CGM - diaTribe.org
Medtronic's Guardian Connect mobile CGM received FDA approval, notable for its smartphone-only display on Apple iOS devices and exclusive access to the Sugar.IQ assistant with Watson, aiming to reduce upfront costs by eliminating a dedicated receiver.
2021-08
Medtronic Newsroom
Real-World Data from Guardian(TM) Connect and Sugar.IQ(TM) Reveal Improved Diabetes Outcomes
Real-world data showed that users of the Guardian Connect system with the Sugar.IQ app experienced a 4.1% increase in Time in Range, representing about one extra hour per day, and a significant reduction in low and high glucose excursions.
2019-06
Medtronic Newsroom
Medtronic Guardianu2122 Connect Continuous Glucose Monitoring (CGM) System for Diabetes Now Compatible with Android Devices
Medtronic announced FDA approval for the Android version of its Guardian Connect CGM system, expanding accessibility and including enhancements like adjustable alert volume and mute options.
2020-05
INESSS
Continuous glucose monitoring system (Guardian Connectu00ae, Medtronic) - INESSS
INESSS, a Canadian health institution, did not recommend public coverage of the Guardian Connect system, stating that its therapeutic value had not been demonstrated, despite its approval for diabetes management in patients aged 3 and older as a complement to fingerstick testing.
2020-10
PubMed
A head-to-head comparison between Guardian Connect and FreeStyle Libre systems and an evaluation of user acceptability of sensors in patients with type 1 diabetes - PubMed
A study comparing Guardian Connect and FreeStyle Libre systems found Guardian Connect to be superior in accuracy, with 90% of participants perceiving it as accurate compared to 40% for FreeStyle Libre, though both were found easy to use and educational.
2022-10
PMC (PubMed Central)
Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts - PMC
A retrospective analysis of Guardian Connect CGM system data showed that predictive alerts helped prevent 59% of low sensor glucose excursions and 39% of high sensor glucose excursions, highlighting the system's effectiveness in proactive diabetes management.
2019-05

Videos

Product demos, reviews, and walkthroughs for Guardian Connect.

Loading videos...

View all on YouTube

Frequently Asked Questions

Guardian Connect uses predictive algorithms to anticipate hypoglycemic and hyperglycemic events up to 60 minutes in advance, providing real-time alerts to patients and caregivers. These algorithms are based on machine learning models trained on continuous glucose monitoring data, aiming to identify trends and patterns indicative of future glucose excursions. The system's AI primarily focuses on pattern recognition and predictive analytics to empower proactive diabetes management.
Guardian Connect adheres to strict data privacy and security protocols, including encryption of all transmitted and stored patient data, to ensure HIPAA compliance. Access to patient health information by AI algorithms is limited to de-identified and aggregated data for model training and improvement, with individual patient data only accessible to authorized users (patient and their designated healthcare providers) through secure, authenticated channels. Regular security audits and assessments are conducted to maintain the highest level of data protection.
While Guardian Connect's AI algorithms are robust, potential limitations or biases can exist, particularly in very rare or atypical physiological responses not extensively represented in training data. Medtronic continuously monitors the algorithm's performance across diverse patient populations and updates it to minimize bias and improve accuracy for all users. Physicians should consider individual patient factors and clinical judgment in conjunction with the device's predictions.
Guardian Connect offers integration capabilities with various EHR systems, allowing for the seamless flow of glucose data and AI-generated insights into a patient's medical record. Physicians can typically access and interpret these insights through a dedicated provider portal or directly within the EHR interface, where data is presented in an organized and actionable format, often including trend reports and alert summaries. Specific integration workflows may vary depending on the EHR system in use.
Several alternatives to Guardian Connect exist in the continuous glucose monitoring market with varying AI capabilities, such as the Dexcom G6 and Abbott FreeStyle Libre systems. Guardian Connect's pricing model typically involves the cost of the Guardian Sensor 3 and the Guardian Link 3 transmitter, often covered by insurance. Pricing can vary based on insurance plans and local distributors, and physicians should compare the overall cost and features with alternative systems to determine the best fit for their patients.
Guardian Connect, including its predictive AI features, has received necessary regulatory clearances, such as FDA approval in the United States, for its intended use. Medtronic conducts ongoing post-market surveillance and real-world evidence studies to continuously monitor the device's performance, safety, and the effectiveness of its AI algorithms. This ensures continued compliance with regulatory standards and informs future product enhancements.
Medtronic provides comprehensive training and support for both physicians and patients to ensure effective utilization of Guardian Connect's AI-driven features. This includes educational materials, online resources, and dedicated support teams to assist with device setup, data interpretation, and troubleshooting. For physicians, specific training on interpreting AI-generated alerts and trends is available to facilitate informed clinical decision-making.

Related Tools

StackAI for Endocrinology Practices
StackAI
Documentation & Scribing
StackAI helps endocrinology practices deploy secure AI agents that automate patient support, summarize clinical context, and streamline document-driven workflows with enterprise governance and HIPAA-ready controls.
Freemium
SNAQ MCP
SNAQ
Developer Tools & APIs
SNAQ MCP Server is a secure connection that lets AI assistants like ChatGPT, Claude, Gemini, Mistral, and Perplexity work with your SNAQ diabetes data. Once connected, you can ask about your glucose curves and patterns, log meals and insulin by chat, and get SNAQ's insights in plain language, all from inside the assistant you already use.
Paid
Scribe4Me AI Medical Scribes for Endocrinology
Scribe4Me AI (a brand of Physicians Angels, Inc.)
Documentation & Scribing
Scribe4Me AI converts doctor-patient conversations into structured clinical notes automatically, aiming to transform practices by saving time and enhancing workflow. They offer both AI-powered Smart Scribe and Hybrid Scribe solutions with human review.
Paid, free trial available
NutriStyle
NutriStyle
Endocrinology & Metabolic AI
NutriStyle is an AI-powered nutrition engine that delivers nutrient-precise, personalized meal plans based on individual health conditions, medications, dietary preferences, and goals, integrating with EMRs and telehealth systems.
Nourish (for providers)
Nourish
Endocrinology & Metabolic AI
Nourish offers an AI-powered platform connecting patients with Registered Dietitians for virtual nutrition counseling, with 94% of patients paying $0 out-of-pocket due to insurance partnerships. The platform includes AI-powered meal logging for patients and AI-driven insights for providers, aiming to make nutrition care more accessible, effective, and human.
Insurance-covered, 94% of patients pay $0 out of pocket.
iHealth
iHealth Labs Inc.
Endocrinology & Metabolic AI
iHealth Labs Inc. offers innovative, consumer-friendly, mobile personal healthcare products connected to the cloud, enabling users to accurately measure, track, and share health vitals. They provide a range of devices including blood pressure monitors, glucose monitors, thermometers, and COVID-19 rapid tests, and were a major supplier of at-home tests during the pandemic.
Varies by product

See all Endocrinology & Metabolic AI tools →

More from Medtronic

LINQ II Insertable Cardiac Monitor
Medtronic
Cardiology AI
The Medtronic LINQ II is an advanced, AI-powered insertable cardiac monitor providing long-term, continuous heart rhythm monitoring with remote programming and enhanced accuracy for diagnosing arrhythmias.
Enterprise
Reveal LINQ
Medtronic
Cardiology AI
Medtronic Reveal LINQ is a tiny, implantable cardiac monitor that continuously records ECG for up to three years, utilizing AccuRhythm™ AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope.
Contact vendor for pricing
Reveal LINQ Insertable Cardiac Monitor
Medtronic
Cardiology AI
The Medtronic LINQ II™ Insertable Cardiac Monitor (ICM) with AccuRhythm™ AI algorithms provides long-term, accurate heart monitoring by using deep learning AI to reduce false alerts and enhance diagnostic yield for conditions like atrial fibrillation and syncope.
Contact vendor

View company profile →

Suggest an Edit → | Last Verified: 2026-08-05 | First Added: 2026-08-05
AI Tool Finder
AI-powered search. Results may not be comprehensive.